Benvenuto nella sezione riservata ai Comunicati Stampa.

In queste pagine, ti offre la possibilità di diffondere gratuitamente e senza alcuna limitazione i tuoi comunicati.

Crea un Nuovo Account

Per poter inserire comunicati stampa su, è necessario creare prima un proprio account.

Inserisci un Comunicato Stampa

Se sei già un utente registrato, vai alla pagina di login per inserire un nuovo comunicato.

Gestisci i Comunicati Stampa inviati

Gli utenti registrati hanno la possibilità di verificare la pubblicazione dei propri comunicati tramite un pannello di controllo riservato.

Richiedi una Nuova Password

Per gli utenti che hanno dimenticato la propria password oppure desiderano modificare quella esistente.

I Comunicati sul tuo Sito

Hai ora la possibilità di visualizzare i comunicati stampa di sul tuo sito mediante un widget, di cui puoi personalizzare sia il contenuto che il formato.

Feed RSS per la notifica dei nuovi comunicati pubblicati su Gli ultimi comunicati stampa

MEDTEC Japan 2016 to be Held in April 2016

Over 500 exhibitors from approximately 25 countries around the world will be exhibiting their latest technologies and services to address the second largest Medical Device market in the world, only after the United States. With the aging population and the government back up, the Medical Device is one of the few markets continuing to grow steadily.
PR Newswire 01/12/2015 03:00

Endometriosis Pipeline H2 2015 Market Research Report

Complete report on Endometriosis Pipeline Review spread across 131 pages, analyzing 22 companies and supported with 43 tables and 16 figures is now available at .
PR Newswire 01/12/2015 03:00

The Medicines Patent Pool (MPP) Signs a Collaborative Agreement with the University of Liverpool to Develop HIV Nanomedicines

The Medicines Patent Pool (MPP) today announced a collaboration with the University of Liverpool and a licence for the university's Solid Drug Nanoparticle (SDN) technology to accelerate the development of WHO-recommended antiretrovirals as nanomedicines. The agreement covers a territory of all 135 low- and middle-income countries and two high-income countries in Africa, where licensees based anywhere in the world will have the right to make, use and distribute lower cost ARVs based on SDN technology.
PR Newswire 01/12/2015 01:01

ICA Enters into Grace Period for Interest Payment on Senior Notes due 2024

MEXICO CITY, Nov. 30, 2015 (GLOBE NEWSWIRE) -- Empresas ICA. S.AB. de C.V. (BMV:ICA) (NYSE:ICA), the largest infrastructure and construction company in Mexico, confirmed today that it has entered into the 30-day grace period with respect to the approximately US$31 million interest payment on its 8.875% senior notes due 2024 (the "2024 Notes"). Under the terms of the indenture governing the 2024 Notes, the use of the 30-day grace period does not result in an event of default...
Thomson Reuters 30/11/2015 23:21

World's Best Student Cities

As the world continues to deal with the aftermath of the Paris attacks, the French capital has again topped the QS Best Student Cities Rankings . It is followed by Melbourne, again second, and Tokyo in third.
PR Newswire 30/11/2015 23:00

Oxford Immunotec Selected to Test New Entrants for TB in UK National Tender

OXFORD, United Kingdom and MARLBOROUGH, Mass., Nov. 30, 2015 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, commercial-stage diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions, today announced that it has been selected by NHS England to provide tuberculosis (TB) testing for persons recently immigrating to England as part of the National Health System's (NHS) new strategy...
Thomson Reuters 30/11/2015 22:49

CHO POWER: FAR Secured at Morcenx

EUROPLASMA (ALEUP, ISIN FR0000044810) announces the successful delivery of a critical milestone, having secured the FAR of the CHO Morcenx advanced gasification plant.
PR Newswire 30/11/2015 20:20

Biocartis Group NV: Biocartis announces launch of Influenza-Respiratory Virus Panel on the Idylla(TM) platform

Mechelen, Belgium, 30 November 2015 - Biocartis (Euronext Brussels: BCART), an innovative molecular diagnostics company, today announces the launch of its first infectious disease test on the Idylla(TM) platform. The Idylla(TM) Respiratory IFV-RSV Panel has been developed by Janssen Diagnostics and is intended for the detection of various strains of Influenza Virus (IFV) and Respiratory Syncytial Virus (RSV)...
Thomson Reuters 30/11/2015 20:13

Vai all'elenco completo...